Tansulosina Mylan

Quick links

Choose a section

Quick links to important sections

Advertisements

Tansulosina Mylan

Selected form

Advertisements
Advertisements

Overview of Tansulosina Mylan

Tansulosina Mylan is a prescription-only medicine for adult men, containing the active substance Tamsulosin Hydrochloride. Its core function is to facilitate the flow of urine by relaxing specific muscles in the lower urinary tract.


Quick Facts

Property Description
Active ingredient Tamsulosin Hydrochloride
Form Modified-release capsule (Oral)
Pharmacological class Selective alpha1-Adrenoceptor Antagonist
General purpose Improving urinary flow and relieving discomfort
Origin Synthetic compound

What Type of Medicine is Tansulosina Mylan?

Tansulosina Mylan is officially classified as a selective alpha1-adrenoceptor antagonist, widely known as an alpha-blocker. The active component, Tamsulosin Hydrochloride, is a synthetic compound that targets receptors predominantly found in the prostate and bladder neck. This targeted action results in uroselectivity, which is a preferential effect on the lower urinary tract smooth muscle.

Unlike older, non-selective alpha-blockers, Tamsulosin Hydrochloride achieves its effect by focusing mainly on these specific alpha receptors. Tamsulosin belongs to this group of drugs that exert a blocking effect on alpha-adrenergic receptors, which works to relax muscles in the prostate and bladder neck to allow urine to flow easily. This specific formulation is produced by Mylan Pharmaceuticals and is presented as a modified-release capsule for oral administration.


Understanding the Modified-Release Capsule

The medication is supplied as an oral dosage form in a modified-release capsule. This specialized design is crucial for its consistent effectiveness. The capsule contains the Tamsulosin Hydrochloride embedded within an internal pharmaceutical matrix, ensuring the drug is released gradually and in a controlled manner into the body over an extended period. This controlled release ensures stable drug concentrations for continuous symptom management, supporting its high-level purpose throughout the daily dosing interval.


What is the General Purpose of Tamsulosin Hydrochloride?

The general purpose of Tamsulosin Hydrochloride is achieved through the relaxation of the smooth muscle tissue in the prostate and bladder neck. By blocking the corresponding alpha receptors, Tamsulosin prevents the muscles from constricting the urinary channel. This physiological effect leads to the widening of the urinary outflow tract, which is the fundamental mechanism for improving urine flow and relieving general discomfort associated with lower urinary tract function.

Regulatory References

  1. NIH MedlinePlus
  2. Public Assessment Report (PAR)
Advertisements

What side effects are possible with Tansulosina Mylan?

Possible Side Effects and Safety Information

The safety profile for Tamsulosin Hydrochloride, the active ingredient in Tansulosina Mylan, is officially documented by frequency of occurrence and categorized by the body's affected System-Organ Class (SOC). This information is derived from clinical trials and post-marketing surveillance data reviewed by regulatory authorities like the FDA and EMA.


Adverse Reactions Classified by Frequency

Classification Examples of Officially Documented Effects
Common (1 to 10 in 100) Dizziness, Headache, Abnormal Ejaculation, Rhinitis.
Uncommon (1 to 10 in 1,000) Orthostatic Hypotension, Gastrointestinal disturbances (e.g., Nausea, Diarrhea, Constipation), Skin reactions (e.g., Rash, Pruritus), Asthenia.
Rare (1 to 10 in 10,000) Syncope (fainting), Angioedema (swelling of the face, tongue, or throat).
Very Rare (Less than 1 in 10,000) Priapism (persistent, painful erection), Stevens-Johnson Syndrome (severe skin reaction).

Regulatory Safety Notes and Restrictions

Official labeling addresses several important safety considerations. Serious adverse reactions that have been documented include Priapism, Angioedema, and Syncope. The medicine is associated with Intraoperative Floppy Iris Syndrome (IFIS), a complication observed during cataract and glaucoma surgery in patients using or previously treated with alpha-blockers.

Regulatory restrictions specify that the medicine is not recommended for use in individuals with severe hepatic or severe renal impairment. Additionally, symptoms of orthostatic hypotension may be more likely to occur upon initiation of treatment or following a dose increase. Use with strong CYP3A4 inhibitors or other alpha-adrenergic blocking agents is generally avoided due to the potential for increased risk of symptomatic hypotension.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Tansulosina Mylan overdose is defined by the potential for severe cardiovascular effects resulting from excessive pharmacological action. Urgent medical assistance must be sought immediately if an overdose is suspected.

Domain Officially Documented Overdose Statement
Overdose Manifestations Documented presentations include acute systemic hypotension, which may be severe (e.g., systolic blood pressure 70 mmHg in a reported case), along with gastrointestinal effects such as vomiting and diarrhoea.
Urgent Medical Action Immediate medical attention must be sought if signs of acute hypotension or potential syncope are observed. Cardiovascular support is explicitly required in such instances to help restore blood pressure and heart rate.

The required management procedures focus on the absence of a specific antidote and controlling systemic absorption. No specific antidote for Tamsulosin is known, and dialysis is unlikely to be helpful due to the drug's high plasma protein binding. Management measures described in official labeling include placing the patient in a lying down position for positional therapy. If necessary, volume expanders may be administered, followed by vasopressors if hypotension persists. To reduce systemic exposure, procedures such as the administration of activated charcoal, an osmotic laxative, or gastric lavage are referenced. Continuous monitoring of renal function is required as part of the general supportive measures.

Advertisements

Therapeutic Uses of Tansulosina Mylan

What Tamsulosina Mylan treats: main uses and benefits

The primary therapeutic use of this medication is the management of Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). This condition involves the non-cancerous enlargement of the prostate gland, which can cause localized discomfort. The medicine is used to provide symptomatic support where physical discomfort interferes with daily functioning, helping to maintain functional stability.

The medication helps relieve LUTS such as difficulty initiating urination, a weak urinary stream, dribbling, and the frequent or urgent need to urinate. It is often utilized during phases when symptoms become more pronounced, providing relief that helps ease the overall symptom burden. This action supports general well-being by helping patients manage these symptoms more steadily.


Quick Fact

May assist with managing symptoms related to difficulty initiating urination.


This treatment is relevant when symptomatic assistance is needed to improve comfort. It contributes to reducing the burden caused by symptoms linked to functional stress on the urinary system.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Tansulosina Mylan?

Regulatory agencies specify that Tansulosina Mylan is indicated only for use in adult men (aged 18 and over). The medicine is not indicated for use in women or the pediatric population. While no overall differences in safety were found in older adults, greater sensitivity in some geriatric patients cannot be ruled out.

Use is contraindicated in patients with a known hypersensitivity to tamsulosin, including a history of drug-induced angioedema. It is also prohibited for individuals with a history of orthostatic hypotension and those with severe hepatic insufficiency. Due to a lack of clinical studies, use in patients with severe renal impairment (creatinine clearance < 10 mL/min) should be approached with caution.

Regulators strictly prohibit concomitant use with other alpha-adrenergic blocking agents and caution against co-administration with strong CYP3A4 inhibitors. Furthermore, therapy initiation is not recommended for patients scheduled for cataract or glaucoma surgery. Patients must also be screened for prostate cancer prior to and during treatment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory authorities document the interaction profile of Tamsulosin Hydrochloride around two main types of interactions: those affecting how the body processes the medicine (pharmacokinetic) and those involving combined effects (pharmacodynamic).


Metabolic Interactions

The medicine is processed primarily by the liver enzymes CYP3 A4 and CYP2 D6. Co-administration with strong CYP3 A4 inhibitors, such as Ketoconazole, is officially contraindicated because it causes a significant increase in Tamsulosin exposure, raising its AUC by a factor of 2.8. Use with strong CYP2 D6 inhibitors, such as Paroxetine, requires caution as it causes a moderate increase in exposure. Caution is also advised when co-administered with moderate inhibitors of these two enzyme systems, including Erythromycin and Cimetidine. This interaction potential is particularly relevant for individuals classified as CYP2 D6 poor metabolizers, where caution is officially advised due to the expected increase in exposure.

Pharmacodynamic and Food Interactions

Interactions involving combined effects are also documented. Co-administration with other alpha adrenergic blocking agents (e.g., Doxazosin) is contraindicated due to the officially noted risk of an additive hypotensive effect. Caution is also required when taking PDE5 inhibitors (e.g., Sildenafil) as this combination poses an increased risk of symptomatic hypotension. The official label notes that the absorption of the Tamsulosin modified-release capsule is affected by concomitant food intake.

Advertisements

Mechanism of Action

Selective Blockade of Alpha-1 Adrenoceptors

The action of Tamsulosin Hydrochloride begins at the molecular level by functioning as a selective competitive antagonist of the alpha1A and alpha1D adrenoceptor subtypes, which are highly concentrated in the smooth muscle of the lower urinary tract. This selective blockade competitively prevents the binding and action of the primary sympathetic neurotransmitter, norepinephrine, thereby interrupting the signaling cascade that normally causes muscle contraction.

Influence on Sympathetic Muscle Tone

By interrupting the continuous sympathetic signaling via these receptors, the drug influences the muscular tension, or tone, within the prostatic capsule and bladder neck. This mechanism leads directly to sustained smooth muscle relaxation, which causes a decrease in the dynamic resistance within the urethral passage. The physiological consequence is an anatomical change in the urinary outflow tract, specifically the dilation of the lumen, correlating with an increase in the maximum flow rate ( Q max).

Mechanistic Scope and Limitations

The drug’s mechanism is entirely confined to regulating the dynamic component of smooth muscle tension, and does not alter the proliferation or physical mass of the prostate tissue. Its high affinity for the alpha1A subtype in the lower urinary tract results in a lower interaction with alpha1B receptors in the vasculature, which accounts for its uroselective physiological consequences.

Advertisements

Dosage and Administration Information

How to Use Tansulosina Mylan

The usage of Tansulosina Mylan, which contains Tamsulosin Hydrochloride, follows standardized protocols to ensure the proper function of its modified-release formulation. This medicine is intended for oral administration and is taken as a **single dose once daily.


Administration Guidelines

Category Instruction
Route of Administration Oral administration.
Dosing Schedule Starting Dose: 0.4 mg once daily. May be increased to a maximum of 0.8 mg once daily for patients who do not adequately respond after a period of 2 to 4 weeks.
Timing in Relation to Meals Administer approximately one-half hour following the same meal each day (e.g., after breakfast).
Special Handling The modified-release capsule must be swallowed whole and must not be crushed, chewed, broken, or opened as this interferes with the intended prolonged-release properties.

Usage Patterns and Specific Populations

The administration schedule is designed to be consistent, with the fixed time relative to a meal being essential for stable drug absorption. If administration is discontinued or interrupted for several days, it is recommended that therapy be restarted at the 0.4 mg once-daily dose.

Dosage adjustments are generally not required for older adult patients (geriatric use) or for those with mild to moderate renal or hepatic impairment. This medicine is not indicated for use in the pediatric population.

Advertisements

Recent Clinical Evidence

Tamsulosin in Benign Prostatic Hyperplasia (BPH)

Tamsulosin, the active component in Tamsulosin Mylan, is an alpha-1 adrenoceptor antagonist frequently studied for the management of Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). Clinical trials have primarily focused on its effect on the symptoms experienced by men with enlarged prostates.

Key research reported that treatment with tamsulosin was associated with a statistically significant improvement in the International Prostate Symptom Score (IPSS) compared to placebo. This improvement was noted for both voiding symptoms (e.g., weak stream, hesitancy) and storage symptoms (e.g., frequency and urgency). These improvements in symptom scores were often observed within the first month of treatment and reported to be stable for up to several years in long-term extension studies.

Efficacy and Safety Profile

Studies also evaluated the effect of tamsulosin on objective measures of urinary flow. Findings from placebo-controlled trials indicated that tamsulosin was associated with an increase in peak urinary flow rate (Qmax) and a reduction in post-void residual (PVR) urine volume compared to baseline. Non-inferiority trials comparing generic tamsulosin products to the original compound typically concluded similar efficacy profiles.

While generally considered well-tolerated in clinical studies, the most common adverse events reported include dizziness, headache, and abnormal ejaculation. The drug is associated with a lower incidence of orthostatic hypotension (a drop in blood pressure upon standing) compared to some older alpha-blockers. Rare but serious risks, such as priapism (prolonged erection) and Intraoperative Floppy Iris Syndrome (IFIS), have been noted, particularly concerning IFIS risk during cataract surgery. The overall safety profile is continuously monitored through real-world pharmacovigilance reports.

Key Studies & References

  1. Label: TAMSULOSIN HYDROCHLORIDE capsule (DailyMed / NIH)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tansulosina Mylan (FAQ)


Q: What specific condition is Tamsulosin Mylan used to treat?

A: Tansulosina Mylan, which contains Tamsulosin Hydrochloride, is officially indicated for the management of the signs and symptoms associated with benign prostatic hyperplasia (BPH). BPH is an enlargement of the prostate gland that can cause lower urinary tract symptoms (LUTS).


Q: What should I do if I accidentally miss a dose of the medication?

A: Official patient information outlines that if a dose is missed, it should be taken as soon as it is remembered. However, if the missed dose is not recalled until the next day, the instruction is to skip the missed dose and take the subsequent dose at the regular time. The labeling advises against taking two doses at the same time to compensate for a forgotten one.


Q: What should I do if I am planning to have cataract or glaucoma surgery?

A: Patients who are considering cataract or glaucoma surgery are advised to inform their ophthalmologist (eye doctor) that they are taking or have previously taken an alpha-blocker like Tamsulosin. This is due to reports of a complication known as Intraoperative Floppy Iris Syndrome (IFIS). The official label notes that the benefit of stopping this medication prior to surgery has not been conclusively established.


Q: How long does it typically take for Tansulosina Mylan to start working and improve BPH symptoms?

A: The official documentation indicates that steady-state concentrations of the drug are typically reached after about five days of once-daily dosing. The documentation also mentions a reassessment period of two to four weeks after starting the initial dose to determine patient response.


Q: What is the appearance or color of the modified-release capsule?

A: According to the official product information, the modified-release capsule is a size ‘0’ hard gelatin capsule. The capsule is described as being olive green opaque/orange opaque and contains white to off-white beadlets.

Advertisements

How should Tansulosina Mylan be stored and disposed of?

Storage and Disposal Requirements

Tansulosina Mylan (Tamsulosin Hydrochloride) must be stored and handled according to specific official regulatory guidelines to maintain its stability and ensure safety.

Storage Conditions

The medicine must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The capsules should be kept in their original container. It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

Do not dispose of unused or expired Tamsulosina Mylan in household waste or by flushing it down the wastewater system (e.g., sink or toilet). For proper disposal, which is required to help protect the environment, the medicine should be returned to a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tansulosina Mylan found in:

A-Z Index: